New inhaled psychedelic drug GH001 enters first human safety trial
NCT ID NCT07540494
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will give a single inhaled dose of GH001 (5-MeO-DMT) to 12 healthy adults. Researchers will measure how the drug moves through the body and check for any side effects. The goal is to gather basic safety information needed before testing the drug in people with medical conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GH001 (5-MeO-DMT, also known as mebufotenin)
What this could lead to
If successful, this study will provide essential safety and dosing data for future trials of GH001 in patients with certain medical conditions.
What could go wrong
This is an early Phase 1 trial in only 12 healthy people, so results may not predict effects in patients. The drug is a psychedelic compound and may cause temporary psychological or physical side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GH Research Clinical Trial Site
Miami, Florida, 33319, United States
Contact